Your gut bacteria can make a molecule from pomegranates that tells tired cells to recycle their broken power plants. The catch: most of the human evidence comes from the company that sells it.
Your cells run on mitochondria, and with age they stop clearing out the broken ones. That cleanup process is called mitophagy, and it slows down as you get older. Urolithin A, a compound your gut bacteria make from pomegranates and walnuts, switched mitophagy back on in lab animals. The real question is whether it does anything useful in people.
Why This Matters
Mitochondria are the parts of your cells that turn food and oxygen into usable energy. You have hundreds to thousands of them in an energy-hungry cell like a muscle fiber or an immune cell. They wear out, leak, and misfire over time.
A healthy cell handles this by recycling the damaged units and building fresh ones. When that quality control fades, broken mitochondria pile up, energy production drops, and inflammation creeps up. This is one of the recognized hallmarks of aging, and it sits close to the center of why tissues lose function with age.
Urolithin A is interesting because it targets that exact step. It is the most clinically advanced compound sold as a mitophagy activator, marketed as Mitopure. The story is genuinely promising in animals. In people it is real but smaller than the marketing suggests, and worth reading carefully.
What Is Mitophagy, and Why Does It Fade With Age?
Mitophagy is a targeted form of autophagy, the cell's recycling system. Autophagy clears out all kinds of cellular junk. Mitophagy is the branch that tags a damaged mitochondrion, wraps it in a membrane, and hauls it to the cell's disposal units to be broken down for parts.
Think of it as quality control on a factory floor. A machine that runs badly does not just waste fuel. It leaks reactive byproducts that damage everything around it. Pulling the bad machine off the line protects the whole plant.
Young cells run this cleanup briskly. With age, the tagging and hauling get sluggish. Damaged mitochondria linger, and the average quality of the pool drops. That decline overlaps with mitochondrial health problems seen in aging muscle, brain, and immune tissue. If you could nudge mitophagy back toward its younger pace, the reasoning goes, you might keep those tissues working longer.
That is the whole premise behind urolithin A.
Where Urolithin A Actually Comes From
Here is the part most headlines skip. You cannot eat urolithin A. It is not in pomegranates.
What pomegranates, walnuts, raspberries, and strawberries contain are large molecules called ellagitannins. When those reach your colon, certain gut bacteria break them down through several steps into urolithin A. The fruit supplies the raw material. Your microbiome does the manufacturing.
And not everyone's microbiome can finish the job. Researchers describe three urolithin metabotypes. People in one group convert ellagitannins efficiently into urolithin A. Others produce different urolithins, and a third group makes almost none at all [6,7]. By one estimate in a 2021 Trends in Molecular Medicine review, only about 40% of people produce urolithin A at meaningful levels from food [6].
That single fact reframes a lot of the pomegranate hype. Two people can eat the same handful of walnuts and end up with very different amounts of the active compound in their blood. A supplement sidesteps the lottery by delivering urolithin A directly, which is exactly why the trials use it rather than fruit.
What the Animal Studies Found
The foundational work was published in Nature Medicine in 2016 by a group led by Dr. Johan Auwerx at EPFL in Switzerland [1]. In the roundworm C. elegans, urolithin A prevented the buildup of failing mitochondria with age and extended lifespan. In aging mice and rats, it improved endurance and muscle function.
The mechanism tracked cleanly. Urolithin A triggered mitophagy, the worms and rodents cleared their damaged mitochondria, and the remaining pool worked better. This is a different route from compounds like NAD+ boosters, which aim to refuel mitochondria rather than recycle the broken ones.
Animal results rarely carry straight over to humans, and lifespan extension in a worm is a long way from anything you can feel. But the signal was consistent and mechanistic, which is what pushed it into human testing.
What Happens in Human Trials?
This is where the honesty has to increase, because the human data are thinner and more mixed than the animal story.
The first human trial, published in Nature Metabolism in 2019, was mostly a safety check [2]. Sedentary older adults took 500 mg or 1,000 mg for 4 weeks. Urolithin A was safe and well tolerated, and it shifted blood markers of mitochondrial activity and muscle gene expression in the expected direction. It did not measure strength or performance. It cleared the runway.
Then came two 4-month trials.
In older adults, a randomized trial published in JAMA Network Open in 2022 by researchers at the University of Washington gave 1,000 mg daily [3]. Muscle endurance improved, measured as the number of contractions before fatigue, and mitochondrial biomarkers moved favorably. But the 6-minute walk distance did not improve significantly. A biomarker and a lab measure of endurance moved. A real-world function test did not.
In middle-aged, overweight, untrained adults, a 2022 trial in Cell Reports Medicine tested 500 mg and 1,000 mg for 4 months [4]. Here is the detail that matters: the primary endpoint, peak power output, was not met. What did improve were secondary measures, including roughly a 12% gain in leg muscle strength and lower levels of C-reactive protein and acylcarnitines, markers of inflammation and mitochondrial strain.
Read those two trials together and a pattern appears. Urolithin A reliably moves mitochondrial and inflammatory biomarkers. It sometimes moves a specific measure of strength or endurance. It has repeatedly failed to move the headline endpoint each trial was designed around. That is a compound with a real biological effect and a modest, uneven functional payoff.
The Newest Twist: The Aging Immune System
The most recent chapter moved away from muscle. In late 2025, a randomized, placebo-controlled trial published in Nature Aging tested urolithin A on immune aging [5].
Fifty healthy adults aged 45 to 70 took 1,000 mg daily for 4 weeks. The trial looked at CD8+ T cells, the immune cells that hunt infected and abnormal cells and that grow exhausted and worn with age. Urolithin A expanded the pool of younger, naive-like, less exhausted CD8+ cells, and it raised their capacity to burn fat for fuel by about 14.72 percentage points compared with placebo.
This fits the mitophagy story. Immune cells are as dependent on clean mitochondria as muscle cells are, arguably more so, because they have to power up fast when they meet a threat. The effect sizes are again small, the trial is short, and it measures cell biology rather than whether anyone caught fewer colds. But it points the mechanism at a tissue where mitochondrial quality clearly matters.
What This Does and Does Not Prove
A 2024 systematic review in Ageing Research Reviews pulled together the human trials to date: five studies, about 250 people [8]. Its summary is the fairest one-line verdict available. Urolithin A raised muscle strength and endurance and lowered inflammation. It had no measurable effect on maximal ATP production, mitochondrial biogenesis, mitochondrial dynamics, body composition, cardiovascular measures, or physical function.
So what can we actually say?
What the human evidence backs:
- In the trials so far, urolithin A was safe over weeks to months at doses up to 1,000 mg [2,3,4].
- It consistently shifts mitochondrial and inflammatory biomarkers.
- It produces small improvements in some measures of muscle endurance, strength, and immune-cell profile.
What remains unproven:
- No human study has tested lifespan or healthspan, the distinction we cover in healthspan vs lifespan.
- Primary endpoints have been missed more often than met.
- The benefits, where real, are modest, not the kind you would notice from your couch.
Compared with a supplement like taurine or the spermidine and autophagy evidence, urolithin A sits in a similar place: a believable mechanism, early human data, and a lot of commercial noise stacked on top of a modest signal.
So What Should You Take From This?
The strongest honest claim is narrow. In humans, urolithin A appears to improve mitochondrial biomarkers and some measures of muscle and immune-cell function, with a clean short-term safety record. That is worth something, especially for older adults losing muscle, but it is not a transformation.
The weakest claim, the one to resist, is that a pomegranate pill will add years to your life. There is no human lifespan data, the functional effects are small, and the primary endpoints keep coming up empty.
If you are curious about trying it, a few things are worth holding in mind:
- The dose used in the trials is 500 to 1,000 mg per day of the supplement form, not eating more fruit [3,4].
- Eating pomegranates and walnuts is still a good idea for other reasons, but only some people's gut bacteria turn them into urolithin A.
- Nothing here beats the basics. Resistance training does more for aging muscle than any current pill, a point we make in exercise and longevity.
Urolithin A is one of the more scientifically grounded entries in a noisy supplement landscape. That is a real compliment and a low bar at the same time.
The Bottom Line
Urolithin A is a gut-bacteria product that switches on mitophagy, the recycling of worn-out mitochondria. In worms and rodents the effect is strong and even extends lifespan. In people it is genuine but modest: better biomarkers, some gains in muscle endurance and strength, an early signal in aging immune cells, and a run of missed primary endpoints. Only about 40% of people make it well from food, which is why the supplement exists. It is safe short-term, unproven long-term, and most of the human evidence traces back to the company that sells it. Promising, not settled.
Frequently Asked Questions
Can I just eat pomegranates instead of taking a supplement? Sometimes, and only if your gut bacteria cooperate. Pomegranates, walnuts, and some berries contain ellagitannins, the raw material, but your microbiome has to convert them into urolithin A. Only about 40% of people do that efficiently. The rest produce little or none. Eating the fruit is still worthwhile for fiber and other compounds, but it is not a reliable way to get a set dose of urolithin A.
Is urolithin A the same as taking NAD+ or NMN? No, and the difference is the interesting part. Compounds like NMN aim to raise NAD+ and refuel mitochondria, which we cover in NMN vs NR. Urolithin A instead triggers mitophagy, the clearing of damaged mitochondria so fresh ones can take over. One tops up the fuel, the other cleans out the broken machinery. They target different problems.
Does urolithin A actually make you live longer? There is no evidence of that in people. Lifespan extension has only been reported in the worm C. elegans. Human trials have measured biomarkers, muscle function, and immune-cell profiles over weeks to months, not survival. Treat any "live longer" claim as marketing that runs well ahead of the data.
Is it safe to take? In the trials so far, yes, over weeks to a few months at doses up to 1,000 mg per day, with a clean tolerability record starting from the first human safety study in 2019. What no one can tell you yet is whether taking it for years is safe or useful, because those trials have not been done. Talk to your doctor before starting any supplement, especially if you take medication.
Who paid for these studies? Most of them were funded or co-authored by Amazentis, the company that sells urolithin A as Mitopure. The trials are peer-reviewed and placebo-controlled, which counts for a lot, but a single company drives most of the human evidence. See the Funding Transparency note below.
Sources
- Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine. 2016;22(8):879-888. PubMed: 27400265.
- Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019;1(6):595-603. PubMed: 32694802.
- Liu S, D'Amico D, Shankland E, et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Network Open. 2022;5(1):e2144279. PubMed: 35050355.
- Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. 2022;3(5):100633. PubMed: 35584623.
- Denk D, Singh A, Kasler HG, et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature Aging. 2025. PubMed: 41174221.
- D'Amico D, Andreux PA, Valdés P, Singh A, Rinsch C, Auwerx J. Impact of the Natural Compound Urolithin A on Health, Disease, and Aging. Trends in Molecular Medicine. 2021;27(7):687-699. PubMed: 34030963.
- Tomás-Barberán FA, González-Sarrías A, García-Villalba R, et al. Urolithins, the rescue of old metabolites to understand a new concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status. Molecular Nutrition & Food Research. 2017;61(1). PubMed: 27158799.
- Kuerec AH, Lim XK, Khoo ALY, et al. Targeting aging with urolithin A in humans: A systematic review. Ageing Research Reviews. 2024;100:102406. PubMed: 39002645.
Funding Transparency
LSD is editorially independent. We receive no funding from pharmaceutical, supplement, or longevity companies. Urolithin A is an unusual case, because most of the human evidence traces back to one commercial source, and readers deserve to know that plainly.
- Amazentis SA (which sells urolithin A as Mitopure, under the Timeline brand) funded or ran most of the human trials cited here. Authors including Anurag Singh, Pénélope Andreux, and Chris Rinsch are affiliated with the company (Sources #2, #4, #5, #6).
- Source #1 (Nature Medicine, 2016): The foundational science came from the lab of Johan Auwerx at EPFL, whose work is tied to the company that commercialized the compound.
- Source #3 (JAMA Network Open, 2022): Run by academic researchers at the University of Washington, but the supplement and funding were provided by Amazentis.
- Sources #7 and #8 are independent academic work: the metabotype research from Tomás-Barberán's group in Spain, and a systematic review from a team at the National University of Singapore and Vrije Universiteit Amsterdam.
None of this makes the findings false. The trials are peer-reviewed and placebo-controlled. But when one company designs, funds, and co-authors most of the studies of its own product, independent replication matters more than usual, and it is still thin.
Related Reading
- Mitochondrial Health and Aging
- Autophagy, Mitophagy, and Alzheimer's
- Spermidine, Autophagy, and Longevity
- NMN vs NR: The NAD+ Precursor Question
- The Supplement Landscape
A pomegranate molecule that tells your cells to take out the trash is a genuinely elegant idea. The biology is real. The human payoff, so far, is small and mostly measured by the people selling it. Both things can be true at once.
This article is for education, not medical advice. Supplements can interact with medication and are not a substitute for exercise, sleep, or a doctor's care. Talk to your healthcare provider before starting urolithin A or any new supplement, especially if you are older or managing a health condition.
Written with the help of AI tools, shaped and verified by humans who care about getting this right.